FACTORS AFFECTING PROGNOSIS AND MORTALITY IN SEVERE COVID-19 PNEUMONIA PATIENTS
Emine Afşin, Muhammed Emin Demirkol, Prof Assoc Emine Afşin, MD Abant Izzet
doi:10.20471/acc.2023.62.01.13
Fatality rate in coronavirus disease 2019 (COVID-19) cases has been reported to be 3.4% worldwide. The aim of this study was to evaluate the factors that determine prognosis and mortality in severe COVID-19 pneumonia patients. Eighty adult patients with severe COVID-19 pneumonia hospitalized and monitored at Izzet Baysal State Hospital (Bolu, Turkey) between August and November 2020 were included in this retrospective single-center study. Demographic and laboratory data, severity of radiological involvement, comorbidities, agents used in treatment, and clinical results were recorded, and data were grouped as survivors and non-survivors. The mean patient age was 67.8±12.6 years. There were 59 (73.8%) male patients. Comorbid diseases were present in 53 (66.3%) patients. There was no significant relationship between patient age, gender, smoking status or presence of comorbidity and mortality (p>0.05). The variables such as pulmonary involvement above 50%, intubation, or ferritin (>434.8 µg/L), troponin I (>14.05 ng/L) and procalcitonin (>0.125 ng/mL) as the sole variables of laboratory data were found to have significant relationship with increased mortality (p<0.05). Mortality was significantly higher in patients using steroid pulse therapy + tocilizumab, steroid pulse therapy + hydroxychloroquine, or solely steroid pulse therapy, while it was significantly lower in patients receiving azithromycin therapy and those in the plasma + steroid pulse therapy group. The severity of pulmonary involvement, intubation, and increase in inflammation markers such as ferritin, troponin and procalcitonin were found to be significantly associated with mortality (p<0.05). Treatment approaches with azithromycin and plasma + steroid pulse therapy were found to reduce mortality.
References
Aktas, A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS-Cov-2 infection, Exp Biomed Res,
doi:10.30714/j-ebr.2020463629Andrianopoulos, Papathanasiou, Papathanakos, Chaidos, Koulouras, Tocilizumab's efficacy in patients with coronavirus disease 2019 (COVID-19) is determined by the presence of cytokine storm, J Med Virol,
doi:10.1002/jmv.26209Fernandez-Cruz, Ruiz-Antoran, Munoz-Gomez, López, Mills-Sánchez et al., A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother,
doi:10.1128/AAC.01168-20Furuta, Takahashi, Fukuda, Kuno, Kamiyama et al., In vitro and in vivo activities of anti-influenza virus compound T-705, Antimicrob Agents Chemother,
doi:10.1128/AAC.46.4.977-981.2002Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends,
doi:10.5582/dst.2020.01047Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein, Impact of sex and gender on COVID-19 outcomes in Europe, Biol Sex Differ,
doi:10.1186/s13293-020-00304-9Guaraldi, Meschiari, Cozzi-Lepri, Milic, Tonelli et al., Tocilizumab in patients with severe COVID-10: a retrospective cohort study. Lancet Rheumatol,
doi:10.1016/S2665-9913Guo, Fan, Chen, Wu, Zhang et al., Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol,
doi:10.1001/jamacardio.2020.1017Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19 -preliminary report, N Engl J Med,
doi:10.1056/NEJMoa2021436Hu, Sun, Dai, Deng, Li et al., Prevalence and severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, J Clin Virol,
doi:10.1016/j.jcv.2020.1043719Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet,
doi:10.1016/S0140-6736Hung, To, Lee, Lee, Yan et al., Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection, Chest,
doi:10.1378/chest.12-2907Mareev, Orlova, Pavlikova, Matskeplishvili, Krasnova et al., Steroid pulse-therapy in patients with COVID-19, systemic inflammation and risk of venous thrombosis and thromboembolism (WAYFARER Study), Kardiologiia,
doi:10.18087/car-dio.2020.6.n1226Monreal, De La Maza, Natera-Villalba, Beltrán-Corbellini, Rodríguez-Jorge et al., High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study, Eur J Clin Microbiol Infect Dis,
doi:10.1007/s10096-020-04078-1Petrak, Skorodin, Van Hise, Fliegelman, Pinsky et al., Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2, Clin Transl Sci,
doi:10.1111/cts.12894Rubio-Rivas, Padulles, Mitjavila, Riera-Mestre, García-Forero, Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness, Int J Infect Dis,
doi:10.1016/j.ijid.2020.09.1486Sažetak, Uzrokovanom, None
Sherren, Ostermann, Agarwal, Meadows, Ioannou et al., COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review, Br J Anaesth,
doi:10.1016/j.bja.2020.08.050Simonovich, Pratx, Scibona, Beruto, Vallone et al., A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med,
doi:10.1056/NEJMoa2031304Sit, Aktas, Ozer, Kocak, Erkus et al., Mean platelet volume: an overlooked herald of malignant thyroid nodules, Acta Clin Croat,
doi:10.20471/acc.2019.58.03.03Stone, Frigault, Serling-Boyd, Fernandes, Harvey et al., Efficacy of tocilizumab in patients hospitalized with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2028836Wadman, Couzin-Frankel, Kaiser, Matacic, How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes, Science
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19), JAMA,
doi:10.1001/jama.2020.12839Xia, Li, Wu, Wang, Zhu et al., Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion, Blood,
doi:10.1182/blood.2020007079DOI record:
{
"DOI": "10.20471/acc.2023.62.01.13",
"ISSN": [
"0353-9466"
],
"URL": "http://dx.doi.org/10.20471/acc.2023.62.01.13",
"author": [
{
"affiliation": [],
"family": "Afşin",
"given": "Emine",
"sequence": "first"
}
],
"container-title": "Acta Clinica Croatica",
"container-title-short": "ACC",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2023,
9,
11
]
],
"date-time": "2023-09-11T09:41:05Z",
"timestamp": 1694425265000
},
"deposited": {
"date-parts": [
[
2023,
9,
11
]
],
"date-time": "2023-09-11T09:41:24Z",
"timestamp": 1694425284000
},
"indexed": {
"date-parts": [
[
2023,
9,
13
]
],
"date-time": "2023-09-13T00:43:23Z",
"timestamp": 1694565803315
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2023
]
]
},
"link": [
{
"URL": "https://hrcak.srce.hr/file/443392",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "8565",
"original-title": [],
"prefix": "10.20471",
"published": {
"date-parts": [
[
2023
]
]
},
"published-print": {
"date-parts": [
[
2023
]
]
},
"publisher": "Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice)",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://hrcak.srce.hr/clanak/443392"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"General Medicine"
],
"subtitle": [],
"title": "Factors Affecting Prognosis and Mortality in Severe COVID-19 Pneumonia Patients",
"type": "journal-article"
}
